Pharmacokinetic-pharmacodynamic (PK-PD) modeling of cardiovascular effects of metoprolol in spontaneously hypertensive rats: a microdialysis study
- 458 Downloads
The present work addressed possible alterations in the pharmacokinetics and the in vivo pharmacodynamic of metoprolol (MET) in spontaneously hypertensive (SH) rats and Wistar Kyoto (WKY) animals by means of the microdialysis technique. The correlation between MET unbound plasma concentrations and its pharmacological effects, such as heart rate and blood pressure change, was also examined in SH and WKY rats by the application of a PK-PD model. MET dialysate concentrations and its chronotropic and blood pressure effect were determined during 3 h after the administration of 3 and 10 mg.kg−1 of the drug. A PK-PD model with a separate effect compartment was used to analyse the data. A good correlation between plasma MET concentrations and its hypotensive and chronotropic effect was found in all experimental groups. Although a greater maximal effect (Emax) for the antihypertensive effect of MET was observed in SH rats (WKY: Emax: −17±1 mmHg; SH: Emax: −28±4 mmHg; P<0.05 versus WKY rats), no differences were found in the concentration yielding half-maximal response (IC50) comparing SH (IC50: 583±146 ng.ml−1) and WKY animals (IC50: 639±187 ng.ml−1). The bradycardic effect of MET was greater in SH rats (Emax: −29±1%, P<0.05 versus WKY rats) than in WK animals (Emax: −22±2%), but no differences were observed in the IC50 comparing both experimental groups (WKY: IC50: 187±53 ng.ml−1; SH: IC50: 216±62 ng.ml−1). Pharmacokinetic analysis shows that the volume of distribution of MET was greater in SH rats (Vd: 3.4±0.5 l, P<0.05 versus WKY rats) with regard to Wistar Kyoto (WKY) animals (Vd: 1.9±0.2 l). The results suggest that the pharmacokinetic behaviour of metoprolol are modified in SH rats, resulting in an increased volume of distribution. A greater maximal efficacy to the hypotensive effect of metoprolol was observed in SH rats, suggesting participation of β-adrenoceptors in the maintenance of the hypertension. Also, a greater chronotropic response to metoprolol was found in the hypertensive group compared with WKY animals, suggesting that, at least in part, the greater cardiac effect of metoprolol explained the enhanced hypotensive response of the beta blocker in the SH animals.
KeywordsSpontaneously hypertension Microdialysis Pharmacokinetic-pharmacodynamic modeling Metoprolol Chronotropic effect Blood pressure
This work was supported by a grant from Secretaría de Ciencia y Técnica, Universidad de Buenos Aires, Argentina.
Dr. Carlos A. Taira is member of Carrera del Investigador, CONICET, Argentina.
- Antonaccio MJ, High J, DeForrest JM, Sybertz E (1986) Antihypertensive effects of 12 beta adrenoceptor antagonists in conscious spontaneously hypertensive rats: relationship to changes in plasma renin activity, heart rate and sympathetic nerve function. J Pharmacol Exp Ther 238:378–387PubMedGoogle Scholar
- Conway FJ, Fitzgerald JD, Mcainsh J, Rowlands DJ, Simpson WT (1976) Human pharmacokinetic and pharmacodynamic studies of atenolol, a new cardioselective beta-adrenoceptor blocking drug. Br J Clin Pharmacol 42:665P–666PGoogle Scholar
- Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Marcel Dekker, New YorkGoogle Scholar
- Hajri T, Ibrahimi A, Coburn CT, Knapp FF, Kurtz T, Praveneci M, Abumrad NA (2001) Defective fatty acid uptake in the spontaneously hypertensive rat is a primary determinant of altered glucose metabolism, hyperinsulinemia, and myocardial hypertrophy. J Biol Chem 276:23661–23666PubMedCrossRefGoogle Scholar
- Leonetti G, Mayer G, Morganti A, Terzoli L, Zanchetti A, Bianchetti G, Di Salle E, Morselli PL, Chidsey CA (1975) Hypotensive and renin-suppressing activities of propranolol in hypertensive patients. Clin Sci Mol Med 48:491–499Google Scholar
- Meredith PA (1997) Clinical relevance of optimal pharmacokinetics in the treatment of hypertension. J Hypertens 15(suppl 5):S27–S31Google Scholar
- Oates JA, Brown NJ (2001) Antihypertensive agents and the drug therapy of hypertension. In: Hardman JG, Limbird LE, Gilman A (eds) Goodman & Gilman’s the pharmacological basis of therapeutics. McGraw Hill, New York, pp 871–900Google Scholar
- von Bahr C, Collste P, Frisk-Holmberg M, Haglund K, Orme M, Ostman J, Sjoqvist F (1976) Plasma levels and effects of metoprolol on blood pressure, adrenergic beta receptor blockade and plasma renin activity in essential hypertension. Clin Pharmacol Ther 20:130–137Google Scholar